TSO3 to Enhance Canadian STERIZONE® Sterilizer - An Advanced Single Cycle to be Offered to Canadian Hospitals
Share:
Ticker:Â TSX - TOS
Shares Outstanding: 83,025,289
QUÉBEC CITY – TSO(3) Inc. (TSX: TOS) ("TSO(3)" or the "Company") an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has submitted required documentation to Health Canada in support of commercializing the STERIZONE® VP4 Sterilizer in Canada. Currently, a three-cycle variation of the device is sold in Canada, which will be replaced with the single-cycle STERIZONE® VP4 Sterilizer. When cleared, the Canadian STERIZONE® VP4 Sterilizer with its advanced technology and single cycle will continue to sterilize the same large, mixed and complex loads sterilized with the prior model including multi-channeled flexible devices, such as colonoscopes.
"Our efforts continue to create the improved standard in healthcare sterile reprocessing" stated Mr. R.M. (Ric) Rumble, President and CEO. "These actions underscore that the data has been reliably reproduced to demonstrate that enhancements made to the product currently sold in the USA can be applied to the Canadian market. Additionally the Company has submitted data to Canadian authorities supporting certain long, multi-channeled flexible endoscopes can be sterilized using the single-cycle of the STERIZONE® VP4 Sterilizer. The Company will offer only the single-cycle STERIZONE® VP4 Sterilizer in Canada moving forward. Current TSO(3) STERIZONE® 125L+ Sterilizer users in Canada will receive field upgrades as per the conditions of their preventive maintenance agreements" explained Mr. Rumble.Â
"While these changes only impact the Canadian market, the Company is preparing the documentation required to expand claims in all markets including the United States", concluded Mr. Rumble.  Â
About the STERIZONE® VP4 low temperature sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO(3) is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H(2)O(2)) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO(3)'s unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
More information about the STERIZONE® VP4 Sterilizer is available through TSO(3)'s website, under the Products section: http://www.tso3.com/en/products/sterizone-vp4/.
About TSO(3)
Founded in 1998, TSO(3)'s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO(3), visit the Company's Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO(3) relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO(3)) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO(3) to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SourceÂ
TSO3 Inc..
ContactT:
R.M. (Ric) Rumble, President and CEO
418 651-0003
Email: info@tso3.com
Web Site: http://www.tso3.com
